T-Cell Therapy Market (7th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indication (Multiple Myeloma, Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma, Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma Acute Myeloid Leukemia, Generalized Myasthenia Gravis (MG), Renal transplantation (HLA-A2), Gastric Adenocarcinoma, Ovarian / Endometrial Cancer, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Renal Cell Carcinoma, Melanoma, Basal Cell Carcinoma, Lung Cancer, Sarcoma, Head And Neck Cancer, Cervical Cancer, Neuro Gastro-Intestinal (GI) Cancer, Breast Cancer, Hepatocellular Carcinoma, Nasopharyngeal Carcinoma and Ovarian Cancer), Target Antigen (BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and Others), Company Size (Small, Mid-sized and Large), Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World), Leading Players and Sales Forecast of Therapies